For a patient on lithium 450 mg twice daily and olanzapine (Zyprexa) 15 mg nightly who continues to have insomnia and pacing (possible akathisia), what additional medication can be given to promote sleep?

Management of Persistent Insomnia and Pacing in a Patient on Lithium and Olanzapine

First, address the pacing as possible akathisia from olanzapine, then optimize sleep management—the most effective evidence-based additions are mirtazapine 15 mg for both akathisia and insomnia, or propranolol 20-40 mg for akathisia with a separate sleep agent if needed.

Differential Diagnosis: Akathisia vs. Mania vs. Primary Insomnia

The pacing behavior requires immediate clarification:

• Akathisia from olanzapine presents as motor restlessness with subjective inner restlessness and an urge to move, manifesting as pacing, rocking, or inability to sit still 1
• Breakthrough mania would show elevated mood, pressured speech, increased goal-directed activity, and racing thoughts beyond just pacing
• Primary insomnia alone would not typically cause daytime pacing

Critical action: Assess for subjective inner restlessness and the compulsive urge to move—if present, this is akathisia and must be treated first, as it significantly worsens quality of life and increases suicide risk 2

Treatment Algorithm

If Akathisia is Present (Pacing + Inner Restlessness):

First-line: Mirtazapine 15 mg nightly is the optimal choice because it addresses both problems simultaneously:

• Most effective for akathisia: Network meta-analysis showed mirtazapine had the greatest efficacy (SMD -1.20) compared to all other agents for antipsychotic-induced akathisia 2
• Proven for treatment-resistant akathisia: Case reports demonstrate complete resolution (Barnes Akathisia Rating Scale from 8 to 0) in severe cases unresponsive to benzodiazepines and anticholinergics 3
• Improves sleep: Sedating properties address the insomnia component 2
• Dose: Start 15 mg at bedtime 2, 3

Alternative if mirtazapine fails or is contraindicated:

• Propranolol 20-40 mg twice daily: Most consistently effective beta-blocker for acute akathisia, though less effective than mirtazapine (SMD -0.78 vs -1.20) 1, 2
• Vitamin B6 600-1200 mg daily: Second most effective option (SMD -0.92) with excellent tolerability 2
• Biperiden 6 mg daily: Anticholinergic option (SMD -1.01) if beta-blockers contraindicated 2

If Pure Insomnia Without Akathisia:

Do NOT add another antipsychotic or increase olanzapine—guidelines explicitly advise against antipsychotics for insomnia due to sparse evidence, significant harms including increased mortality in elderly patients, and metabolic risks 4

Evidence-based options in order of preference:

1. Low-dose doxepin 3-6 mg nightly: Improves sleep efficiency, sleep onset latency, and total sleep time with minimal adverse events at low doses 4

2. Non-benzodiazepine hypnotics (zolpidem, eszopiclone, zaleplon): Improve sleep efficiency and sleep quality, but use lowest effective dose for shortest duration due to FDA warnings about complex sleep behaviors 4

3. Avoid these agents per guidelines:

   • Benzodiazepines: Harms (dependency, falls, cognitive impairment, respiratory depression) outweigh benefits 4
   • Trazodone 50-150 mg: No difference vs placebo in sleep efficiency or discontinuation rates, with unfavorable adverse effect profile 4
   • Antihistamines: Tolerance develops after 3-4 days, strong recommendation to avoid in older adults per Beers Criteria 4

Monitoring and Adjustments

• Check lithium level: Ensure therapeutic range (0.6-1.2 mEq/L) as subtherapeutic levels may contribute to breakthrough symptoms 5
• Olanzapine dose: Current 15 mg is within therapeutic range (5-20 mg/day); increasing further risks more akathisia and metabolic effects 5
• If mirtazapine added: Monitor for weight gain and sedation; most patients tolerate 15 mg well 2, 3
• If propranolol added: Check blood pressure and heart rate; avoid in asthma/COPD 1

Common Pitfalls to Avoid

• Do not add quetiapine for sleep: Despite off-label use, evidence is sparse with small samples and short durations, and all antipsychotics carry significant harms including metabolic syndrome and increased mortality risk 4
• Do not assume pacing is just insomnia: Akathisia is frequently missed and causes severe distress, non-adherence, and suicide risk 2
• Do not use benzodiazepines long-term: While clonazepam may help acutely, dependency and cognitive effects make it inappropriate for chronic use 4, 1
• Do not increase olanzapine dose: Higher doses increase akathisia risk and metabolic complications without addressing the underlying sleep problem 5